Vaccination drives in the U.S. have led to a significant control over the spreading of the aforementioned diseases. The U.S. vaccine market is broadly categorized into the human vaccine market on the one hand, and the animal vaccine market on the other. A few of the key factors that drive the U.S. vaccine market are greater awareness, high demand for poultry vaccines stemming from the increasing consumption of chicken in the U.S., and also the high incidence of zoonotic diseases leading to greater need for animal vaccination.
Browse Market Research Report of U.S. Vaccine Market: http://www.transparencymarketresearch.com/us-vaccine-market.html
Also, the fact that vaccines nowadays hardly exhibit any harmful or fatal side effects, is stimulating the overall demand in the U.S. vaccine market. Steep logistical costs associated with vaccines, high costs of developing newer vaccines, and stringent regulatory norms are the glaring challenges faced by most companies operating in the U.S. vaccine market.
Growing Importance of the DNA Vaccine Market in the U.S. Market
The U.S. vaccine market is anticipated to expand robustly in the forecasting horizon owing to the rapidly expanding segment for adult vaccines. Industry trends suggest that the success of the U.S. vaccine market will depend immensely on the growth of global DNA vaccines market. Rapid advancements in immunobiology and DNA synthesis play a key role in contributing substantially to the U.S. vaccine market.
The introduction of DNA vaccines has resulted in the discovery of a host of highly advanced vaccines that aim at treating a variety of diseases. This is enabling numerous pharmaceutical companies to create high value and highly sophisticated vaccines for newer applications, which in turn will lead to several opportunities for further expansion of the U.S. vaccine market. The rapid development of DNA vaccines can be attributed to the growth of nanotechnology and newer biotechnologies.
Browse Market Research Press Release of U.S. Vaccine Market: http://www.transparencymarketresearch.com/pressrelease/us-vaccine-market.htm
Active Immunization: A Key Focus Area in the U.S. Vaccine Market
The key companies in the U.S. vaccine market are Zoetis Inc., Sanofi SA, Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline plc, and Boehringer Ingelheim. In January 2015, Switzerland based provider of healthcare solutions, got FDA (Food and Drug Administration) approval for Bexsero vaccine, which is a preventive measure against invasive meningococcal disease.
Meningitis B causes this disease in young adults and adolescents, for which the only vaccine which was approved in America is the Bexsero vaccine developed by Novartis. The approval of this vaccine is a major milestone for Novartis, towards preventing the onset of this devastating disease affecting mostly children and teenagers.
In March 2015, France based pharmaceutical firm, Sanofi SA got a nod from FDA for launching the Quadracel vaccine for immunization against diseases such as pertussis, diphtheria, poliomyelitis, and tetanus in children between the age group of 4 to 6 years.